Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

A view to natural killer cells in hepatitis C.

Shoukry NH, Pelletier S, Chang KM.

Gastroenterology. 2011 Oct;141(4):1144-8. doi: 10.1053/j.gastro.2011.08.025. Epub 2011 Aug 27. No abstract available.

PMID:
21875586
2.

Early changes in natural killer cell function indicate virologic response to interferon therapy for hepatitis C.

Ahlenstiel G, Edlich B, Hogdal LJ, Rotman Y, Noureddin M, Feld JJ, Holz LE, Titerence RH, Liang TJ, Rehermann B.

Gastroenterology. 2011 Oct;141(4):1231-9, 1239.e1-2. doi: 10.1053/j.gastro.2011.06.069. Epub 2011 Jul 7.

3.

The multifaceted functions of ribavirin: antiviral, immunomodulator, or both?

Mondelli MU.

Hepatology. 2014 Oct;60(4):1126-9. doi: 10.1002/hep.27186. Epub 2014 Jun 26. No abstract available.

PMID:
24753082
4.

Acute exacerbation among chronic hepatitis C patients: tip of the iceberg that deserves more attention.

Wong RJ, Cheung RC.

Clin Gastroenterol Hepatol. 2013 Sep;11(9):1181-2. doi: 10.1016/j.cgh.2013.05.023. Epub 2013 Jun 2. No abstract available.

PMID:
23735449
5.

[Information for patients. Treatment of acute hepatitis C].

Otón Nieto E.

Rev Esp Enferm Dig. 2011 Oct;103(10):549. Spanish. No abstract available.

6.

The end of the beginning for hepatitis C treatment.

Dieterich D.

Hepatology. 2012 Mar;55(3):664-5. doi: 10.1002/hep.25528. No abstract available.

PMID:
22174100
7.

Scleromyxedema secondary to hepatitis C virus and successfully treated with antiviral therapy.

Smith JA, Kalimullah FA, Erickson CP, Peng LS.

Dermatol Online J. 2015 Sep 17;21(9). pii: 13030/qt1vt8c3vt.

PMID:
26437283
8.

The role of liver iron in hepatitis C antiviral treatment.

Musallam KM, Sharara AI, Inati A, Taher AT.

Eur J Gastroenterol Hepatol. 2010 Jun;22(6):769. doi: 10.1097/MEG.0b013e32832e0a56. No abstract available.

PMID:
20440118
9.
10.

Seventy-two weeks of peginterferon and ribavirin for patients with partial early virologic response?

Hoefs JC, Morgan TR.

Hepatology. 2007 Dec;46(6):1671-4. No abstract available.

PMID:
18046713
11.

Pegylated interferon and ribavirin in real life: efficacy versus effectiveness.

de Mattos AZ, de Almeida PR, Tovo CV, de Mattos AA.

Hepatology. 2010 Nov;52(5):1867. doi: 10.1002/hep.23824. No abstract available.

PMID:
20726033
12.

Hepatitis C: Enhancing treatment for hepatitis C among drug users.

Grebely J, Dore GJ.

Nat Rev Gastroenterol Hepatol. 2011 Jan;8(1):11-3. doi: 10.1038/nrgastro.2010.186. Epub 2010 Nov 30. No abstract available.

PMID:
21119610
13.

Catatonia associated with pegylated interferon-α 2b and ribavirin for hepatitis C.

Quinn D, Kuchler E, Deming P, Arora S.

Psychosomatics. 2012 Jul-Aug;53(4):400-1. doi: 10.1016/j.psym.2012.02.007. No abstract available.

PMID:
22748752
14.

[Treatment with pegylated interferon and ribavirin in patients co-infected by human immunodeficiency virus and hepatitis C virus].

Marcos Sánchez F, Albo Castaño MI, Casallo Blanco S.

Rev Clin Esp. 2007 Mar;207(3):150-1; author reply 151-2. Spanish. No abstract available.

PMID:
17397643
15.

[Hepatitis C].

Pache I, Gonvers JJ.

Rev Med Suisse Romande. 2002 Oct;122(10):507-12. French. No abstract available.

PMID:
12494784
16.

Older age per se has negative effect on hepatitis C patients treated with peginterferon and ribavirin.

Chen TM, Tung JN.

Am J Gastroenterol. 2009 Aug;104(8):2117-9. doi: 10.1038/ajg.2009.256. No abstract available.

PMID:
19661945
17.

PegIFN/ribavirin during acute HCV coinfection.

Bernard EJ.

IAPAC Mon. 2004 Jul;10(7):260-1. No abstract available.

PMID:
15624247
18.

Pegylated interferon-alpha2a and ribavirin in HIV-hepatitis C coinfected patients.

[No authors listed]

Expert Rev Anti Infect Ther. 2004 Jun;2(3):341-2. No abstract available.

PMID:
15490503
19.

[Long-acting interferon: studies on pegylated interferon].

Ma H, Wang H.

Zhonghua Gan Zang Bing Za Zhi. 2002 Feb;10(1):78-9. Review. Chinese. No abstract available.

PMID:
11856520
20.

Supplemental Content

Support Center